The direct answer

Yes. Ozempic is officially sold in India as of December 2025. It is manufactured by Novo Nordisk in Denmark, imported into India, and distributed nationally. As of February 2026, Novo Nordisk also partnered with Abbott India to commercialise a second brand of the same molecule called Extensior, identical to Ozempic and aimed at expanding pharmacy reach beyond cities Novo Nordisk traditionally serves.

The dose strengths currently available in India are 0.25 mg, 0.5 mg and 1 mg, all delivered through a once-weekly FlexTouch pre-filled pen. The 1.7 mg and 2.4 mg strengths sold globally are reserved in India for Wegovy, which holds the obesity indication.

Ozempic is a Schedule H prescription-only drug — no licensed Indian pharmacy can legally dispense it without a registered medical practitioner's prescription.

Talk to an AIIMS-trained doctor.

2-minute eligibility test. Free. We'll see if Kaivo is the right fit for you.

Ozempic vs Wegovy vs Rybelsus — same molecule, different India status

All three are semaglutide — the same active molecule. The differences are dose, route, indication, and the regulatory label CDSCO has approved.

If your doctor prescribes "semaglutide for diabetes," any of these three is technically a valid option — your decision is driven by needle vs tablet preference, target dose, and clinical fit. If your prescription is "semaglutide for weight loss in a non-diabetic," only Wegovy is on-label; using Ozempic or Rybelsus for that indication is off-label prescribing. For the molecule in detail, see our semaglutide guide.

How to legally access semaglutide in India in 2026

You now have multiple legal routes. The grey market is no longer an excuse — every route below is regulated, traceable, and prescription-controlled.

Five legal pathways

  1. Branded Ozempic (Novo Nordisk) — T2D only. Prescription from a registered physician. Buy from a licensed pharmacy (Apollo, Tata 1mg, PharmEasy, Netmeds, Wellness Forever, MedPlus, hospital pharmacies). Cold-chain delivery is now standard at the top four online pharmacies.
  2. Extensior (Abbott India, same molecule, T2D). Launched February 2026 in partnership with Novo Nordisk. Identical product, broader distribution into Tier 2/3 cities. Same prescription requirement.
  3. Wegovy (Novo Nordisk) — obesity / overweight with comorbidity. Once-weekly pen, prescription-only, available in all major pharmacies since June 2025.
  4. Rybelsus (oral semaglutide) — T2D only. The tablet alternative for needle-averse patients; daily dosing.
  5. Generic semaglutide injections — from March 2026. After the patent expired on 20 March 2026, brands from Sun Pharma, Dr Reddy's, Zydus, Natco, Eris, Alkem, Lupin and others entered the market. Brand availability varies by city; ask your prescriber or telehealth provider which generic they trust.

Named-patient import under Rule 36 (Drugs & Cosmetics Rules, 1945) — historically the only legal route to bring Ozempic into India when Novo Nordisk hadn't launched locally — is no longer relevant. With Ozempic CDSCO-approved and sold domestically, Kaivo doesn't recommend personal import.

Why Ozempic took so long

Until December 2025, the answer to "is Ozempic available in India" was "no." The reasons were strategic, not regulatory.

Novo Nordisk prioritised Wegovy first. Globally, Wegovy carried higher margins per pen and a larger addressable population than Ozempic. The company delivered Wegovy in June 2025, almost a year ahead of its earlier 2026 plan.

Global supply constraints were real. Novo Nordisk's production facilities were running 24/7 with over USD 23 billion of capital expenditure in 2023–2024 to scale capacity in Denmark, Ireland, the United States and France. India, with weaker price realisation than the US or Europe, sat lower in the global allocation queue.

Eli Lilly's Mounjaro launch forced Novo's hand. Lilly launched tirzepatide in India on 20 March 2025, undercutting Novo Nordisk by 15 months. Novo's late entry was described as "converting a mistake into an opportunity" — pricing both Wegovy and Ozempic below international list prices and launching second brands (Poviztra with Emcure for Wegovy, Extensior with Abbott for Ozempic) to defend share before generics arrived. See our Mounjaro guide for the parallel story.

The patent cliff was looming. Novo Nordisk's compound patent for semaglutide in India expired on 20 March 2026. Launching Ozempic in late 2025 gave the company barely a quarter of patent-protected revenue — but waiting longer would have ceded the diabetes pen market to local generics from day one.

What about generic semaglutide?

This is the most consequential part of the Indian GLP-1 story.

Patent expiry: Novo Nordisk's primary Indian compound patent on semaglutide expired on 20 March 2026. Within 48 hours, multiple Indian manufacturers launched semaglutide products.

Companies that have launched as of May 2026:

Industry trackers expect 40–50 generic brands within 12–18 months of patent expiry.

CDSCO regulatory pathway: Generic injectable semaglutide is classified as a peptide biological-similar and approvals are processed under the New Drugs and Clinical Trials Rules, 2019 via the CDSCO SUGAM portal. The four largest Indian generic semaglutide brands — Dr Reddy's, Sun, Zydus, Alkem — were approved under CDSCO's Subsequent New Drug pathway, which required Phase III trials in Indian patients. That is a more demanding pathway than the US FDA's bioequivalence-only generic route.

Grey market and counterfeit Ozempic — the safety case

Even with Ozempic now legal and available, online sellers continue to advertise "imported Ozempic" at suspicious prices on WhatsApp, Telegram, Instagram and certain marketplaces. Do not buy these products.

The international evidence is unambiguous:

Counterfeit pens may contain the wrong active ingredient, an incorrect dose, insulin, no active ingredient at all, or unsterile excipients. There is no consumer-protection recourse when you buy outside the licensed pharmacy chain. Cold-chain integrity — semaglutide must be stored at 2–8°C — is almost never preserved in grey-market shipments.

Three rules to stay safe: buy only from a CDSCO-licensed pharmacy with a valid Indian doctor's prescription on file. Verify the brand against the CDSCO list of DCGI-approved semaglutide products. If a price looks too good to be true, assume it is, until the brand's DCGI approval is confirmed.

What this means if you want to start treatment

Three patient archetypes show up at our consultations every week.

"I specifically want Ozempic"

You can get it. Get a consultation with a physician registered to prescribe Schedule H drugs, complete baseline labs (HbA1c, fasting glucose, renal panel, lipid profile, thyroid history), and order from a licensed pharmacy. If your indication is type 2 diabetes, Ozempic or Extensior is appropriate. If your indication is weight loss without diabetes, your physician will more likely prescribe Wegovy, because that's the on-label semaglutide for obesity. See our diabetes guide for the broader T2D context.

"I want effective GLP-1 treatment and don't care which brand"

You have the most options. Discuss with your prescriber: injection vs tablet (Wegovy/Ozempic/generic injection vs Rybelsus); semaglutide vs tirzepatide (Wegovy/Ozempic vs Mounjaro); branded vs generic semaglutide. Quality differences between CDSCO-approved generics and the originator are minimal for most patients; device convenience and supply reliability are often the deciding factor.

"I tried to buy online and was quoted suspicious prices"

Walk away. A 1 mg Ozempic pen advertised for an unusually low price, an unbranded "semaglutide vial" without a CDSCO-registered manufacturer, a Telegram seller offering "free shipping from Turkey/UAE," or a website asking for cryptocurrency are all red flags. Bring screenshots to your clinical consultation; your doctor can help you identify the correct legal product.

  1. Business Standard, "Novo Nordisk launches Ozempic in India," 12 December 2025.
  2. Abbott India press release, "Abbott partners with Novo Nordisk India to launch Extensior," 27 February 2026.
  3. Bloomberg, "Dr Reddy's to Launch Generic Ozempic in India From March," 21 January 2026.
  4. CDSCO approval notification: Ozempic 26 September 2025; Mounjaro KwikPen August 2025.
  5. Reuters / Invezz, "Novo Nordisk India price cuts on Ozempic and Wegovy," 31 March 2026.
  6. Drugs and Cosmetics Act, 1940; Rules, 1945 (Schedule H, Rule 36).